
    
      Patients who met the study entry criteria were randomized (2:1:2:1) to one of the 4 dosage
      groups (Alfuzosin 0.1 mg/kg/day, matching placebo 0.1 mg/kg/day, Alfuzosin 0.2 mg/mg/kg,
      matching placebo 0.2 mg/kg/day).

      Patients received their treatment using either solution or tablet formulation depending on
      age as follows:

        -  Solution to children 2-7 years of age or, children and adolescents 8-16 years of age if
           they were unable to swallow tablets or they preferred to take the solution or if they
           had a body weight < 30kg. The daily dose was devided in 3 doses given at at breakfast,
           lunch and dinner.

        -  Tablet to children and adolescents 8-16 years of age who were able to swallow tablets
           and had a body weight â‰¥ 30kg. The daily dose was devided in 2 doses given at at
           breakfast and dinner.

      Patients who have completed the 12-week double-blind phase were offered to continue in the
      40-week open-label extension study.

        -  Patients receiving Alfuzosin continued with their dosing regimen.

        -  Patients receiving Placebo were switched to Alfuzosin with a dose corresponding to their
           randomization dose group.

      All patients had a one-week follow-up period after last dose intake.
    
  